新闻资讯
科思
/
/
/
Midterm results of endovascular treatment of superficial femoral artery disease with biodegradable stents:single-center experience

Midterm results of endovascular treatment of superficial femoral artery disease with biodegradable stents:single-center experience

  • 分类:学术论文
  • 作者:
  • 来源:
  • 发布时间:2016-08-12 09:25
  • 访问量:

【概要描述】To assess the midterm efficacy of a biodegradable poly-l-lactic acid (PLLA) stent in the treatment of superficial femoral artery (SFA) occlusive disease.

Midterm results of endovascular treatment of superficial femoral artery disease with biodegradable stents:single-center experience

【概要描述】To assess the midterm efficacy of a biodegradable poly-l-lactic acid (PLLA) stent in the treatment of superficial femoral artery (SFA) occlusive disease.

  • 分类:学术论文
  • 作者:
  • 来源:
  • 发布时间:2016-08-12 09:25
  • 访问量:
详情

  PURPOSE: To assess the midterm efficacy of a biodegradable poly-l-lactic acid (PLLA) stent in the treatment of superficial femoral artery (SFA) occlusive disease.

  MATERIALS AND METHODS: Between June 2009 and April 2011, 35 de novo SFA lesions were treated with 43 biodegradable stents. This nonrandomized, retrospective, single-center study included patients with moderate or severe claudication, lower-limb rest pain, or ischemic ulceration restricted to the toes; symptoms were classified as Rutherford category 2 (48.6%), 3 (37.1%), 4 (8.6%), or 5 (5.7%). The population included 28 men and had a mean age of 71 years (range, 51-81 y). Follow-up included clinical examination and color-flow duplex imaging. Mean follow-up was 38.3 months (range, 30-58 mo).

  RESULTS: Technical success was reported in all patients (100%). There were no intraoperative or immediate (< 30 d) complications.. During follow-up, one in-stent occlusion and seven in-stent restenoses occurred, all of which were successfully treated with percutaneous transluminal angioplasty. Primary and secondary patency rates were 77.1% and 97.1% at 24 and 36 months, respectively. No stent recoil or stent fracture was encountered. Late follow-up (> 12 mo) by ultrasound confirmed total reabsorption of the stent structures. Clinical improvement (ie, an upward shift of at least two Rutherford categories) was achieved in all 35 patients.

  CONCLUSIONS: Midterm results for biodegradable PLLA stents for atherosclerotic SFA lesions were associated with high technical success and secondary patency rates, without stent recoil and vessel remodeling.

中国生物材料学会材料生物力学分会换届大会圆满召开
2022 12-08

中国生物材料学会材料生物力学分会换届大会圆满召开

精准植入 完美心舒——冠脉支架定位系统
2022 11-27

精准植入 完美心舒——冠脉支架定位系统

北京阿迈特与北京航空航天大学联合参与生物医疗器械国家急需高层次人才培养专项
2022 11-26

北京阿迈特与北京航空航天大学联合参与生物医疗器械国家急需高层次人才培养专项

公司信息

北京阿迈特医疗器械有限公司

Beijing Advanced Medical Technologies,Ltd.Inc.

联系我们

地址:北京市大兴区永旺西路26号院中关村医疗器械园11号楼

电话:010-6297-7955             邮箱:amt@ametcorp.com

联系我们

地址:北京市大兴区永旺西路26号院中关村医疗器械园11号楼

电话:010-6297-7955             

邮箱:amt@ametcorp.com